PMC5780314_01
Pelvis magnetic resonance imaging (MRI) revealed a 3.9 cm sized cervical mass without parametrial and vaginal extension.
ogs-61-165-g001.jpg
PMC5780314_01_ogs-61-165-g001.jpg
F1
And there is no evidence of significant LN metastasis and other local invasion in pelvic cavity (Fig. 1).
The positron emission tomography-computed tomography (PET-CT) scan showed a heterogenous, moderate fluorodeoxyglucose (FDG) uptake in uterus area which was suspected of malignancy, but there is no significant abnormal FDG uptake to suggest metastatic lymph node (LN) and distant metastasis.
ogs-61-165-g002.jpg
PMC5780314_01_ogs-61-165-g002.jpg
F2
The PET-CT scan showed a heterogenous, moderate fluorodeoxyglucose (FDG) uptake in uterus area which was suspected of malignancy, but there is no significant abnormal FDG uptake to suggest metastatic LN and distant metastasis (Fig. 2).
Histologic (A-D; Hematoxylin and Eosin stain) and immunohistochemical (E; p16 stain, F; CK7 stain) findings. (A) Microscopic examination shows atypical glands extended below the normal level expected for benign endocervical glands. The glands are irregular and dilated with gastric differentiation. (B) The tumor shows gastric type differentiation with abundant clear or pale, eosinophilic cytoplasm with atypical nucleus. (C) The tumor invades the myometrium. (D) Tumor cells metastasize to the regional lymph nodes. (E, F) Immunohistochemical stains are negative for p16 (E), positive for CK7 (F).
ogs-61-165-g003.jpg
PMC5780314_01_ogs-61-165-g003.jpg
F3
Immunohistochemical stains are negative for p16, positive for CK7 (Fig. 3).